Low-Intensity Focused Ultrasound Targeting the Stellate Ganglion for Regulating Autonomic Nerve Function and Sleep Quality in Perioperative Patients With Cardiovascular Diseases

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-79
SponsorRenmin Hospital of Wuhan University

About this trial

The goal of this multicenter, double-blind, randomized controlled trial is to evaluate the efficacy and safety of low-intensity focused ultrasound (LIFU) stellate ganglion modulation for improving autonomic function and sleep quality in perioperative cardiovascular disease patients.

The main questions it aims to answer are:

1. Does LIFU improve heart rate variability and sleep characteristics from baseline at 3-7 days post-surgery compared to sham ultrasound? 2. Does LIFU improve serological markers, vital signs, Pittsburgh Sleep Quality Index (PSQI), and reduce \>30-second perioperative arrhythmias? 3. What is the safety profile of LIFU in this population? 200 eligible patients will be randomized 1:1 to receive either active LIFU (2.0W, 1MHz, 50% duty cycle, 30min daily for 3-7 days) plus standard care, or identical sham ultrasound plus standard care. A four-party double-blind design (subjects, operators, assessors, analysts) will be implemented. The study will run from May 1, 2026 to April 1, 2027 at 6 centers in China.

Participants will:

1. Complete pre-surgery screening and baseline assessments (PSQI, 12h ECG/sleep monitoring, residual blood sample collection) 2. Receive daily assigned ultrasound intervention for 3-7 consecutive days post-surgery 3. Undergo 72h continuous ECG monitoring post-surgery, and repeat assessments at 3-7 days 4. Have all adverse events and arrhythmias recorded throughout the study 5. May withdraw voluntarily at any time without affecting routine medical care

Eligibility criteria

Qualifiers

Diagnosed with cardiovascular disease (CVD) and scheduled to undergo cardiology-related surgical treatment

Able to receive and tolerate the aforementioned cardiology-related surgical treatment

Aged between 18 and 79 years (inclusive), with no restriction on gender

Agree to accept random allocation of the treatment strategies

Disqualifiers

Have used sedative-hypnotic drugs, antipsychotic drugs, opioid analgesics, antihistamines, non-steroidal anti-inflammatory drugs (NSAIDs), central nervous system (CNS) stimulant drugs, or any other medications that alter sleep architecture within the past 30 days

Have a history of cervical infection, trauma, severe cervical deformity, or prior cervical surgery

Unable to complete the daily study intervention as required by the trial protocol

Are participating in another clinical trial, or have participated in other clinical trials with interventions that may interfere with the results of this study

Trial design

Treatments tested in this trial

  • Low-intensity focused ultrasound (LIFU) targeting the left stellate ganglion
  • Sham low-intensity focused ultrasound targeting the left stellate ganglion

Treatment groups

200 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Renmin Hospital of Wuhan University

Lead sponsor

Yichang Central People's Hospital

Collaborator

Wuhan Central Hospital

Collaborator

Huangshi Central Hospital

Collaborator

Wuhan Third Hospital

Collaborator

Xiangyang Central Hospital

Collaborator

Jingzhou Central Hospital

Collaborator